Mayne Pharma
Shawn Patrick O’Brien has more than 35 years of global pharmaceutical industry experience building successful enterprises. He is the founding partner of Key BioPharma Partners providing advice to life science companies and capital providers. Previously, he was the Chairman and CEO of Genomind, a personalised mental health platform company and President and CEO of Cipher Pharmaceuticals, Inc., a specialty pharmaceutical company with a portfolio of commercial stage dermatology products. He was also President and CEO of three private biotechs including AltheRx Pharmaceuticals, Profectus BioSciences Inc. and Solstice Neurosciences. Mr O’Brien spent 17 years with AstraZeneca where he held multiple senior leadership positions in Canada and the US including Vice President of Commercial Operations for Emerging Brands, Vice President and Therapy Area Leader, Respiratory and Inflammation and Commercial and Development Group Director for the Oncology Therapeutic area. Mr O’Brien began his career at the Upjohn Company of Canada (part of Pfizer).
Mr O’Brien is the Non-executive Chairman of SFA Therapeutics and Alto Pharma. He is a board member and Co-Chair of the Hubert J.P. Schoemaker Classic (golf charity fundraiser) and an advisory board member of Greater Philadelphia Life Sciences Congress. He was a 9-year Board member of the Crozer Keystone Hospital System, a former board member of Cyrano, LLC and Melanovus LLC.
Mr O’Brien holds a Bachelor of Science in Microbiology and Immunology from the University of Western Ontario.
This person is not in any teams
This person is not in any offices
Mayne Pharma
1 followers
Mayne Pharma Group Ltd is an Australia-based specialty pharmaceutical company. The Company is focused on commercializing branded and generic pharmaceuticals. It operates through four segments: Generic Products (GPD), Specialty Brands (SBD), Metrics Contract Services (MCS) and Mayne Pharma International (MPI). The GPD segment is engaged in the manufacture and distribution of generic pharmaceutical products in the United States. The SBD segment markets and distributes specialty branded pharmaceutical products in the United States. The MCS segment is engaged in the provision of contract analytical and pharmaceutical development services to third-party customers in the United States. The MPI segment is engaged in Australian manufacture and sale of branded and generic pharmaceutical product globally and provision of contract manufacturing services to third-party customers within Australia.